Abstract
Background and Aim: Recently, the association of the dysfunction of programmed cell death (PD)-1 expressed on activated lymphocytes with the pathogenesis of autoimmune hepatitis (AIH) has been speculated. This study aimed to investigate the association of serum anti-PD-1 antibodies with clinical characteristics of type 1 AIH. Methods: Serum samples before the initiation of prednisolone treatment were obtained from 52 type 1 AIH patients, 24 patients with drug-induced liver injury (DILI), 30 patients with acute viral hepatitis (AVH), 11 patients with primary sclerosing cholangitis (PSC), and 62 healthy volunteers. Titers of serum anti-PD-1 antibodies were measured by indirect enzyme-linked immunosorbent assay. The cutoff level was represented by a mean absorbance+2 standard deviations in healthy volunteers. Results: Prevalence of serum anti-PD-1 antibodies was 63% in type 1 AIH patients, 8% in DILI patients, 13% in AVH patients, 18% in PSC patients, and 3% in healthy volunteers. In type 1 AIH patients, titers of serum anti-PD-1 antibodies were correlated with serum levels of bilirubin (r=0.31, P=0.030) and alanine aminotransferase (r=0.31, P=0.027) but not serum immunoglobulin G levels. Positivity for serum anti-PD-1 antibodies was associated with the later normalization of serum alanine aminotransferase levels after the initiation of prednisolone and the disease relapse. Conclusions: Serum anti-PD-1 antibodies would be useful for the discrimination of type 1 AIH from DILI, AVH, and PSC as an auxiliary diagnostic marker. Furthermore, anti-PD-1 antibodies may be associated with clinical characteristics of type 1 AIH.
| Original language | English |
|---|---|
| Pages (from-to) | 110-115 |
| Number of pages | 6 |
| Journal | Journal of Gastroenterology and Hepatology (Australia) |
| Volume | 29 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2014 |
Fingerprint
Keywords
- Acute viral hepatitis
- Autoimmune hepatitis
- Drug-induced liver injury
- Primary sclerosing cholangitis
- Programmed cell death-1
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
Cite this
Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. / Matsumoto, Kazuyuki; Miyake, Yasuhiro; Matsushita, Hiroshi; Ohnishi, Atsuyuki; Ikeda, Fusao; Shiraha, Hidenori; Takaki, Akinobu; Nouso, Kazuhiro; Yamamoto, Kazuhide.
In: Journal of Gastroenterology and Hepatology (Australia), Vol. 29, No. 1, 01.2014, p. 110-115.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis
AU - Matsumoto, Kazuyuki
AU - Miyake, Yasuhiro
AU - Matsushita, Hiroshi
AU - Ohnishi, Atsuyuki
AU - Ikeda, Fusao
AU - Shiraha, Hidenori
AU - Takaki, Akinobu
AU - Nouso, Kazuhiro
AU - Yamamoto, Kazuhide
PY - 2014/1
Y1 - 2014/1
N2 - Background and Aim: Recently, the association of the dysfunction of programmed cell death (PD)-1 expressed on activated lymphocytes with the pathogenesis of autoimmune hepatitis (AIH) has been speculated. This study aimed to investigate the association of serum anti-PD-1 antibodies with clinical characteristics of type 1 AIH. Methods: Serum samples before the initiation of prednisolone treatment were obtained from 52 type 1 AIH patients, 24 patients with drug-induced liver injury (DILI), 30 patients with acute viral hepatitis (AVH), 11 patients with primary sclerosing cholangitis (PSC), and 62 healthy volunteers. Titers of serum anti-PD-1 antibodies were measured by indirect enzyme-linked immunosorbent assay. The cutoff level was represented by a mean absorbance+2 standard deviations in healthy volunteers. Results: Prevalence of serum anti-PD-1 antibodies was 63% in type 1 AIH patients, 8% in DILI patients, 13% in AVH patients, 18% in PSC patients, and 3% in healthy volunteers. In type 1 AIH patients, titers of serum anti-PD-1 antibodies were correlated with serum levels of bilirubin (r=0.31, P=0.030) and alanine aminotransferase (r=0.31, P=0.027) but not serum immunoglobulin G levels. Positivity for serum anti-PD-1 antibodies was associated with the later normalization of serum alanine aminotransferase levels after the initiation of prednisolone and the disease relapse. Conclusions: Serum anti-PD-1 antibodies would be useful for the discrimination of type 1 AIH from DILI, AVH, and PSC as an auxiliary diagnostic marker. Furthermore, anti-PD-1 antibodies may be associated with clinical characteristics of type 1 AIH.
AB - Background and Aim: Recently, the association of the dysfunction of programmed cell death (PD)-1 expressed on activated lymphocytes with the pathogenesis of autoimmune hepatitis (AIH) has been speculated. This study aimed to investigate the association of serum anti-PD-1 antibodies with clinical characteristics of type 1 AIH. Methods: Serum samples before the initiation of prednisolone treatment were obtained from 52 type 1 AIH patients, 24 patients with drug-induced liver injury (DILI), 30 patients with acute viral hepatitis (AVH), 11 patients with primary sclerosing cholangitis (PSC), and 62 healthy volunteers. Titers of serum anti-PD-1 antibodies were measured by indirect enzyme-linked immunosorbent assay. The cutoff level was represented by a mean absorbance+2 standard deviations in healthy volunteers. Results: Prevalence of serum anti-PD-1 antibodies was 63% in type 1 AIH patients, 8% in DILI patients, 13% in AVH patients, 18% in PSC patients, and 3% in healthy volunteers. In type 1 AIH patients, titers of serum anti-PD-1 antibodies were correlated with serum levels of bilirubin (r=0.31, P=0.030) and alanine aminotransferase (r=0.31, P=0.027) but not serum immunoglobulin G levels. Positivity for serum anti-PD-1 antibodies was associated with the later normalization of serum alanine aminotransferase levels after the initiation of prednisolone and the disease relapse. Conclusions: Serum anti-PD-1 antibodies would be useful for the discrimination of type 1 AIH from DILI, AVH, and PSC as an auxiliary diagnostic marker. Furthermore, anti-PD-1 antibodies may be associated with clinical characteristics of type 1 AIH.
KW - Acute viral hepatitis
KW - Autoimmune hepatitis
KW - Drug-induced liver injury
KW - Primary sclerosing cholangitis
KW - Programmed cell death-1
UR - http://www.scopus.com/inward/record.url?scp=84897584800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897584800&partnerID=8YFLogxK
U2 - 10.1111/jgh.12340
DO - 10.1111/jgh.12340
M3 - Article
C2 - 23869988
AN - SCOPUS:84897584800
VL - 29
SP - 110
EP - 115
JO - Journal of Gastroenterology and Hepatology (Australia)
JF - Journal of Gastroenterology and Hepatology (Australia)
SN - 0815-9319
IS - 1
ER -